Conference Reports for NATAP

66th Annual Meeting of the American Association for the Study of Liver Diseases Boston, MA Nov 13-17 2015 Back

SURVEYOR-II: High SVR4 Rates Achieved With the Next Generation NS3/4A Protease Inhibitor ABT-493 and NS5A Inhibitor ABT-530 in Non-Cirrhotic Treatment-Naïve and Treatment-Experienced Patients With HCV Genotype 2 Infection       Reported by Jules Levin AASLD 66th Annual Meeting of the American Association for the Study of Liver Diseases San Francisco, CA 17 November 2015   David Wyles,1 Mark Sulkowski,2 Stanley Wang,3 Michael Bennett,4 Hugo E. Vargas,5 J. Scott Overcash,6 Benedict Maliakkal,7 Asma Siddique,8 Bal Raj Bhandari,9 Fred Poordad,10 Sandra S. Lovell,3 Chih-Wei Lin,3 Teresa I. Ng,3 Federico J. Mensa,3 Jens Kort3   1University of California San Diego, La Jolla, CA, USA; 2Johns Hopkins University School of Medicine, Baltimore, MD, USA; 3AbbVie Inc., North Chicago, IL, USA; 4San Diego Digestive Disease Consultants, Inc., and Medical Associates Research Group, Inc., San Diego, CA, USA; 5Mayo Clinic, Phoenix, AZ, USA; 6eStudySite, San Diego, CA, USA; 7University of Rochester Medical Center, Rochester, NY, USA; 8Virginia Mason Hospital and Medical Center, Seattle, WA, USA; 9Gastroenterology & Nutritional Medical Services, Bastrop, LA, USA; 10Texas Liver Institute, University of Texas Health Science Center, San Antonio, TX, USA